Therapeutic approaches to diastolic dysfunction

Current Hypertension Reports

Volumn 11, Issue 4, 2009, Pages 283-291

  Janardhanan, Rajesh ^a   Desai, Akshay S ^a   Solomon, Scott D ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALAGEBRIUM; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FASUDIL; IRBESARTAN; LOOP DIURETIC AGENT; MCC 135; NEBIVOLOL; NIFEDIPINE; NITRATE; PERINDOPRIL; PLACEBO; PROPRANOLOL; RAMIPRIL; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG; VERAPAMIL;

ARTERIAL STIFFNESS; BLOOD PRESSURE REGULATION; CARDIOVERSION; CLINICAL TRIAL; COMORBIDITY; CORONARY ARTERY BYPASS GRAFT; DIASTOLIC DYSFUNCTION; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; ENDOCARDIAL DISEASE; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE FILLING PRESSURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART MUSCLE ISCHEMIA; HEART MUSCLE RELAXATION; HEART RATE; HUMAN; HYPERTENSION; MORTALITY; NEUROENDOCRINE SYSTEM; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PERICARDIAL DISEASE; PREVALENCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM RETENTION; SYMPTOM; TISSUE DOPPLER IMAGING; TRANSLUMINAL CORONARY ANGIOPLASTY; VENOUS CONGESTION; CARDIAC MUSCLE; DIASTOLIC HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; UNITED STATES;

HEART FAILURE, DIASTOLIC; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MYOCARDIUM; STROKE VOLUME; UNITED STATES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 67651167041     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-009-0048-z     Document Type: Review

References (61)

1. Gaasch WH, Zile MR: Left ventricular diastolic dysfunction and diastolic heart failure. Annu Rev Med 2004, 55: 373-394.
2. Aurigemma GP, Gaasch WH: Diastolic heart failure. N Engl J Med 2004, 351: 1097-1105.
3. Redfield MM, Jacobsen SJ, Burnett JC Jr, et al.: Burden of systolic and diastolic ventricular dysfunction in the community: Appreciating the scope of the heart failure epidemic. JAMA 2003, 289: 194-202.
4. Zile MR, Brutsaert DL: New concepts in diastolic dysfunction and diDstolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. Circulation 2002, 105: 1387-1393.
5. Zile MR, Baicu CF, Gaasch WH: Diastolic heart failure - abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004, 350: 1953-1959.
6. Gaasch WH: Diagnosis and treatment of heart failure based on left ventricular systolic or diastolic dysfunction. JAMA 1994, 271: 1276-1280.
7. Vasan RS, Larson MG, Benjamin EJ, et al.: Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999, 33: 1948-1955.
8. Bhatia RS, Tu JV, Lee DS, et al.: Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006, 355: 260-269.
9. How to diagnose diastolic heart failure. European Study Group on Diastolic Heart Failure. Eur Heart J 1998, 19: 990-1003.
10. Boyer JK, Thanigaraj S, Schechtman KB, et al.: Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Am J Cardiol 2004, 93: 870-875.
11. Aurigemma GP, Gottdiener JS, Shemanski L, et al.: Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: The cardiovascular health study. J Am Coll Cardiol 2001, 37: 1042-1048.
12. Owan TE, Hodge DO, Herges RM, et al.: Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006, 355: 251-259.
13. O'Connor CM, Gattis WA, Shaw L, et al.: Clinical characteristics and long-term outcomes of patients with heart failure and preserved systolic function. Am J Cardiol 2000, 86: 863-867.
14. Brogan WC 3rd, Hillis LD, Flores ED, et al.: The natural history of isolated left ventricular diastolic dysfunction. Am J Med 1992, 92: 627-630.
15. Hunt SA, Abraham WT, Chin MH, et al.: ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005, 112: E154-e235.
16. Brucks S, Little WC, Chao T, et al.: Contribution of left ventricular diastolic dysfunction to heart failure regardless of ejection fraction. Am J Cardiol 2005, 95: 603-606.
17. Wachtell K, Smith G, Gerdts E, et al.: Left ventricular filling patterns in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study). Losartan Intervention For Endpoint. Am J Cardiol 2000, 85: 466-472.
18. Ho CY, Sweitzer NK, McDonough B, et al.: Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation 2002, 105: 2992-2997.
19. Schillaci G, Pasqualini L, Verdecchia P, et al.: Prognostic significance of left ventricular diastolic dysfunction in essential hypertension. J Am Coll Cardiol 2002, 39: 2005-2011.
20. McLaurin LP, Rolett EL, Grossman W: Impaired left ventricular relaxation during pacing-induced ischemia. Am J Cardiol 1973, 32: 751-757.
21. Angeja BG, Grossman W: Evaluation and management of diastolic heart failure. Circulation 2003, 107: 659-663.
22. Cain BS, Meldrum DR, Joo KS, et al.: Human SERCA2a levels correlate inversely with age in senescent human myocardium. J Am Coll Cardiol 1998, 32: 458-467.
23. Kitzman DW, Little WC, Brubaker PH, et al.: Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 2002, 288: 2144-2150.
24. Zile MR, Brutsaert DL: New concepts in diastolic dysfunction and diaCtolic heart failure: Part II: causal mechanisms and treatment. Circulation 2002, 105: 1503-1508.
25. Weber KT, Brilla CG: Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991, 83: 1849-1865.
26. Dahlöf B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002, 359: 995-1003.
27. Rapp JA, Gheorghiade M: Role of neurohormonal modulators in heart failure with relatively preserved systolic function. Cardiol Clin 2008, 26: 23-40, vi.
28. Khan NU, Movahed A: The role of aldosterone and aldosterone-receptor antagonists in heart failure. Rev Cardiovasc Med 2004, 5: 71-81.
29. Park JB, Touyz RM, Chen X, et al.: Chronic treatment with a superoxide dismutase mimetic prevents vascular remodeling and progression of hypertension in salt-loaded stroke-prone spontaneously hypertensive rats. Am J Hypertens 2002, 15: 78-84.
30. Nagata K, Obata K, Xu J, et al.: Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension 2006, 47: 656-664.
31. Paulus WJ, Tschope C, Sanderson JE, et al.: How to diagnose diastolic heart failure: A consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007, 28: 2539-2550.
32. Bergstrom A, Andersson B, Edner M, et al.: Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). Eur J Heart Fail 2004, 6: 453-461.
33. Setaro JF, Zaret BL, Schulman DS, et al.: Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. Am J Cardiol 1990, 66: 981-986.
34. Flather MD, Shibata MC, Coats AJ, et al.: Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005, 26: 215-225.
35. Borlaug BA, Melenovsky V, Russell SD, et al.: Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation 2006, 114: 2138-2147.
36. Wachtell K, Bella JN, Rokkedal J, et al.: Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Circulation 2002, 105: 1071-1076.
37. Zusman RM, Christensen DM, Federman EB, et al.: Nifedipine, but not propranolol, improves left ventricular systolic and diastolic function in patients with hypertension. Am J Cardiol 1989, 64: 51F-61F.
38. Schulman SP, Weiss JL, Becker LC, et al.: The effects of antihypertensive therapy on left ventricular mass in elderly patients. N Engl J Med 1990, 322: 1350-1356.
39. Brooks WW, Bing OH, Robinson KG, et al.: Effect of angiotensin-converting enzyme inhibition on myocardial fibrosis and function in hypertrophied and failing myocardium from the spontaneously hypertensive rat. Circulation 1997, 96: 4002-4010.
40. Tang WH, Parameswaran AC, Maroo AP, et al.: Aldosterone receptor antagonists in the medical management of chronic heart failure. Mayo Clin Proc 2005, 80: 1623-1630.
41. Yamamoto K, Masuyama T, Sakata Y, et al.: Roles of renin-angiotensin and endothelin systems in development of diastolic heart failure in hypertensive hearts. Cardiovasc Res 2000, 47: 274-283.
42. Klingbeil AU, Schneider M, Martus P, et al.: A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003, 115: 41-46.
43. Cleland JG, Tendera M, Adamus J, et al.: The Perindopril in Elderly People with Chronic Heart Failure (PEP-CHF) study. Eur Heart J 2006, 27: 2338-2345.
44. Corea L, Cardoni O, Fogari R, et al.: Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: A comparative study of the efficacy and safety against amlodipine. Clin Pharmacol Ther 1996, 60: 341-346.
45. Johnston CI: Angiotensin II type 1 Aeceptor blockade: a novel therapeutic concept. Blood Press Suppl 2000, 1: 9-13.
46. Diez J, Querejeta R, Lopez B, et al.: Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 2002, 105: 2512-2517.
47. Devereux RB, Dahlof B, Gerdts E, et al.: Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004, 110: 1456-1462.
48. Epstein BJ, Anderson S: Discordant effects of beta-blockade on central aortic systolic and brachial systolic blood pressure: Considerations beyond the cuff. Pharmacotherapy 2007, 27: 1322-1333.
49. Dahlof B, Sever PS, Poulter NR, et al.: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet 2005, 366: 895-906.
50. Yusuf S, Pfeffer MA, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Lancet 2003, 362: 777-781.
51. Mottram PM, Haluska B, Leano R, et al.: Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 2004, 110: 558-565.
52. Kunis R, Greenberg H, Yeoh CB, et al.: Coronary revascularization for recurrent pulmonary edema in elderly patients with ischemic heart disease and preserved ventricular function. N Engl J Med 1985, 313: 1207-1210.
53. Janardhanan R, DTley WL, Naqvi TZ, et al.: Rationale and design: the VALsartan In Diastolic Dysfunction (VALIDD) Trial: Evolving the management of diastolic dysfunction in hypertension. Am Heart J 2006, 152: 246-252.
54. Solomon SD, Janardhanan R, Verma A, et al.: Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: A randomised trial. Lancet 2007, 369: 2079-2087.
55. Massie BM, Carson PE, McMurray JJ, et al.: Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008, 359: 2456-2467.
56. Yip GW, Wang M, Wang T, et al.: The Hong Kong diastolic heart failure study: A randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart 2008, 94: 573-580.
57. Little WC, Zile MR, Kitzman DW, et al.: The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail 2005, 11: 191-195.
58. Zile M, Gaasch W, Little W, et al.: A phase II, double-blind, randomized, placebo-controlled, dose comparative study of the efficacy, tolerability, and safety of MCC-135 in subjects with chronic heart failure, NYHA class II/III (MCC-135-GO1 study): Rationale and design. J Card Fail 2004, 10: 193-199.
59. Lewis GD, Semigran MJ: The emerging role for type 5 phosphodiesterase inhibition in heart failure. Curr Heart Fail Rep 2006, 3: 123-128.
60. Fukui S, Fukumoto Y, Suzuki J, et al.: Long-term inhibition of Rho-kinase ameliorates diastolic heart failure in hypertensive rats. J Cardiovasc Pharmacol 2008, 51: 317-326.
61. Phrommintikul A, Tran L, Kompa A, et al.: Effects of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction. Am J Physiol Heart Circ Physiol 2008, 294: H1804-H1814.